TY - JOUR
T1 - MicroRNA characteristics in epithelial ovarian cancer
AU - Prahm, Kira Philipsen
AU - Høgdall, Claus Kim
AU - Karlsen, Mona Aarenstrup
AU - Christensen, Ib Jarle
AU - Novotny, Guy Wayne
AU - Høgdall, Estrid
PY - 2021
Y1 - 2021
N2 - The purpose of the current study was to clarify differences in microRNA expression according to clinicopathological characteristics, and to investigate if miRNA profiles could predict cytoreductive outcome in patients with FIGO stage IIIC and IV ovarian cancer. Patients enrolled in the Pelvic Mass study between 2004 and 2010, diagnosed and surgically treated for epithelial ovarian cancer, were used for investigation. MicroRNA was profiled from tumour tissue with global microRNA microarray analysis. Differences in miRNA expression profiles were analysed according to histologic subtype, FIGO stage, tumour grade, type I or II tumours and result of primary cytoreductive surgery. One microRNA, miR-130a, which was found to be associated with serous histology and advanced FIGO stage, was also validated using data from external cohorts. Another seven microRNAs (miR-34a, miR-455-3p, miR-595, miR-1301, miR-146-5p, 193a-5p, miR-939) were found to be significantly associated with the clinicopathological characteristics (p ≤ 0.001), in our data, but mere not similarly significant when tested against external cohorts. Further validation in comparable cohorts, with microRNA profiled using newest and similar methods are warranted.
AB - The purpose of the current study was to clarify differences in microRNA expression according to clinicopathological characteristics, and to investigate if miRNA profiles could predict cytoreductive outcome in patients with FIGO stage IIIC and IV ovarian cancer. Patients enrolled in the Pelvic Mass study between 2004 and 2010, diagnosed and surgically treated for epithelial ovarian cancer, were used for investigation. MicroRNA was profiled from tumour tissue with global microRNA microarray analysis. Differences in miRNA expression profiles were analysed according to histologic subtype, FIGO stage, tumour grade, type I or II tumours and result of primary cytoreductive surgery. One microRNA, miR-130a, which was found to be associated with serous histology and advanced FIGO stage, was also validated using data from external cohorts. Another seven microRNAs (miR-34a, miR-455-3p, miR-595, miR-1301, miR-146-5p, 193a-5p, miR-939) were found to be significantly associated with the clinicopathological characteristics (p ≤ 0.001), in our data, but mere not similarly significant when tested against external cohorts. Further validation in comparable cohorts, with microRNA profiled using newest and similar methods are warranted.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Biomarkers, Tumor/genetics
KW - Carcinoma, Ovarian Epithelial/genetics
KW - Female
KW - Gene Expression Profiling/methods
KW - Gene Expression Regulation, Neoplastic/genetics
KW - Humans
KW - MicroRNAs/genetics
KW - Middle Aged
KW - Ovarian Neoplasms/genetics
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85107334819&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0252401
DO - 10.1371/journal.pone.0252401
M3 - Journal article
C2 - 34086724
VL - 16
SP - e0252401
JO - PLOS ONE
JF - PLOS ONE
SN - 1932-6203
IS - 6
M1 - e0252401
ER -